Skip to main content
Isomer
  1. Home
  2. Automated
  3. NDF A-Z listing
  4. Ezetimibe + Simvastatin
E

Ezetimibe + Simvastatin

Subsidy Information and Financing Scheme

No

Drug Guidance

Yes

Post-marketing information

No

Summary of Biologics

No

Active ingredients: Ezetimibe | Simvastatin

General information

Subsidy Information and Financing Scheme

Not Applicable

Drug Guidance for Subsidy

02/05/2019 Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Ezetimibe 10 mg tablet for treating primary (heterozygous familial and non-familial) hypercholesterolaemia in adults as:

    • Add-on therapy to statins when the cholesterol concentration therapeutic target is not achieved at the maximum tolerated statin dose; or

    • Monotherapy as an alternative to statins for adults who are intolerant of, or contraindicated to, statin therapy.

Intolerance to statin therapy is defined as the occurrence of clinically significant adverse effects that are an unacceptable risk to the patient.

Subsidy status

[R] Ezetimibe 10 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

[NR] SDL subsidy does not apply to ezetimibe/simvastatin 10/10 mg or 10/20 mg tablets.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Legend list

Indicator

Legend

R

Recommended for subsidy

NR

Not recommended for subsidy

General Availability in Public Healthcare Institution

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Drug availability

Formulation

Public Healthcare Institution

Tablet, Ezetimibe 10 mg + Simvastatin 10 mg

  1. Alexandra Hospital

  2. National University Hospital

Tablet, Ezetimibe 10 mg + Simvastatin 20 mg

  1. Alexandra Hospital

  2. National University Hospital

  3. Tan Tock Seng Hospital

Registered Product(s) Information

Clinical and product info

Clinical info

Product Info

Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch.

The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice.

Information available here are product details as registered with the HSA. As this website is updated

monthly, please refer to HSA Infosearch for the most updated product information.

Oral

* The following products do not have any clinical information available

Back to top